Back to Search
Start Over
Evaluating ivosidenib for the treatment of acute myeloid leukemia.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Dec; Vol. 21 (18), pp. 2205-2213. Date of Electronic Publication: 2020 Aug 18. - Publication Year :
- 2020
-
Abstract
- Introduction: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, but the results for patients with AML are still unsatisfactory. The discovery of new mutations in AML, including IDH mutations, has opened the door for treatment with targeted agents. Ivosidenib is a selective, potent inhibitor of the IDH1 mutant protein.<br />Areas Covered: This review summarizes the mechanism of action, safety profile and efficacy of ivosidenib for patients with IDH1-mutated AML. The authors then provide their expert perspectives on the use of the drug including their future perspectives.<br />Expert Opinion: Ivosidenib is a promising, most probably practice changing, new drug for the treatment of IDH1-mutated AML. Current phase III trials are ongoing to evaluate the addition of ivosidenib to the current standards-of-care. In the near future, more drug combinations are awaited. Challenges for the future include the development of resistance and establishing the duration of maintenance therapy.
- Subjects :
- Adult
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Antineoplastic Agents blood
Clinical Trials as Topic
Dose-Response Relationship, Drug
Glycine administration & dosage
Glycine adverse effects
Glycine blood
Glycine therapeutic use
Humans
Isocitrate Dehydrogenase genetics
Leukemia, Myeloid, Acute enzymology
Mutation
Pyridines administration & dosage
Pyridines adverse effects
Pyridines blood
Treatment Outcome
Antineoplastic Agents therapeutic use
Glycine analogs & derivatives
Isocitrate Dehydrogenase antagonists & inhibitors
Leukemia, Myeloid, Acute drug therapy
Pyridines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 21
- Issue :
- 18
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 32808831
- Full Text :
- https://doi.org/10.1080/14656566.2020.1806822